The expression of hepatoma-derived growth factor in primary central nervous system lymphoma and its correlation with angiogenesis, proliferation and clinical outcome

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Li, San Zhong ^a   Zhao, Yong Bo ^a   Cao, Wei Dong ^a   Qu, Yan ^a   Luo, Peng ^a   Zhen, Hai Ning ^a   Chen, Xiao Yan ^a   Yan, Zhi Feng ^a   Fei, Zhou ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CD31; Hepatoma derived growth factor (HDGF); Ki67; Primary central nervous system lymphoma (PCNSL); Prognosis

Indexed keywords

CD31 ANTIGEN; HEPATOMA DERIVED GROWTH FACTOR; KI 67 ANTIGEN; HEPATOMA-DERIVED GROWTH FACTOR; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER PROGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; TUMOR GROWTH; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE COURSE; GENETICS; LYMPHOMA; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ANTIGENS, CD31; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; LYMPHOMA; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84878816658     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0622-8     Document Type: Article

References (25)

1. Yang SH, Lee KS, Kim IS, Hong JT, Sung JH, Son BC, et al. Long-term survival in primary CNS lymphoma treated by highdose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant. J Neurooncol. 2009;92(1):65-71.
2. Henry JM, Heffner RR Jr, Dillard SH, Earle KM, Davis RL. Primary malignant lymphomas of the central nervous system. Cancer. 1974;34(4):1293-1302.
3. Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol. 1999;43(3):241-7.
4. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20(24):4643-8.
5. Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol. 2010;67(2):182-9.
6. Nakamura H, Izumoto Y, Kambe H, Kuroda T, Mori T, Kawamura K, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem. 1994;269(40): 25143-9.
7. Everett AD, Stoops T, McNamara CA. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem. 2001; 276(40):37564-8.
8. Okuda Y, Nakamura H, Yoshida K, Enomoto H, Uyama H, Hirotani T, et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci. 2003;94(12):1034-41.
9. Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, Huang CH, et al. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol. 2012;57(3):584-91.
10. Thirant C, Galan-Moya EM, Dubois LG, Pinte S, Chafey P, Broussard C, et al. Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a Novel Angiogenic Secreted Factor. Stem Cells. 2012. doi:10.1002/stem. 1062.
11. Liu YF, Zhao R, Guo S, Wang XQ, Lian PL, Chen YG, et al. Expression and clinical significance of hepatoma-derived growth factor as a prognostic factor in human hilar cholangiocarcinoma. Ann Surg Oncol. 2011;18(3):872-9.
12. Wang S, Fang W. Increased expression of hepatoma-derived growth factor correlates with poor prognosis in human nasopharyngeal carcinoma. Histopathology. 2011;58(2):217-24.
13. Li M, Shen J, Wu X, Zhang B, Zhang R, Weng H, et al. Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion. Med Oncol. 2013;30(2):587.
14. Hsu SS, Chen CH, Liu GS, Tai MH, Wang JS, Wu JC, et al. Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas. J Neurooncol. 2012;107(1):101-9.
15. Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, et al. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2004;22(16):3230-7.
16. de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805-12.
17. Retraction. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol. 2009;62:128-38. doi:10.1136/jcp.2008.057257)
18. J Clin Pathol. 2012;65(9):861-2.
19. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1-8.
20. Nameki N, Tochio N, Koshiba S, Inoue M, Yabuki T, Aoki M, et al. Solution structure of the PWWP domain of the hepatomaderived growth factor family. Protein Sci. 2005;14(3):756-64.
21. Corry J, Smith JG, Wirth A, Quong G, Liew KH. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys. 1998;41(3):615-20.
22. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18(17): 3144-50.
23. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, et al. High-dose chemotherapy with autologous stemcell transplantation and hyperfractionated radiotherapy as firstline treatment of primary CNS lymphoma. J Clin Oncol. 2006;24(24):3865-70.
24. Ekenel M, Iwamoto FM, Ben-Porat LS, Panageas KS, Yahalom J, DeAngelis LM, et al. Primary central nervous systemlymphoma: the role of consolidation treatment after a complete response to highdose methotrexate-based chemotherapy. Cancer. 2008;113(5): 1025-31.
25. Ortega-Paino E, Fransson J, Ek S, Borrebaeck CA. Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. Blood. 2008;111(3):1617-24.